Andreas Schmidt


National University of Singapore

Approximately 20% of people worldwide will be diagnosed with cancer during their lifetime. Despite tremendous progress in developing precision therapies, 75% of cancer treatment eventually fail, and 9.6 million lives are lost to cancer every year. Why do we still fail to treat cancer? It is because tumors are heterogeneous. Different tumor clones and patient specific immune responses lead to differential therapeutic impacts. Proteona is turning a laboratory tool breakthrough, single cell multi-omics, into a weapon against cancer. We profile tumors at the single cell level, simultaneously collecting gene and protein information. We then use Proteona’s AI tools to compare each tumor profile to a proprietary database, matching those molecular signatures to real life drug response data in order to predict which drugs will kill off all of tumor cells. Proteona’s mission is to tailor treatment truly to the unique tumor makeup of each patient for multiple myeloma and other cancers.

More Venture Finalists

All Venture Finalists